Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Nov 2024

Yuan Zhennan, Wang Xueying, Qin Boyu, Hu Rulong, Miao Rui, Zhou Yang, Wang Lei, Liu Tong

Abstract excerpt

Immunotherapy has revolutionized cancer treatment, yet the efficacy of immunotherapeutic approaches remains limited. Resistance to ferroptosis is one of the reasons for the poor therapeutic outcomes in tumors with Kelch-like ECH-associated protein 1 (KEAP1) mutations. However, the specific mechanisms by which KEAP1-mutant tumors resist immunotherapy are not fully understood. In this study, we showed that the loss...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis

Share to Immunotherapy

Share to Kelch-Like ECH-Associated Protein 1

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Neoplasms

Share to NF-E2-Related Factor 2

Source

Identifiers

PMID: 39490240
DOI: 10.1016/j.drup.2024.101160

Genes

KEAP1
NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers.PMID 39490240Read ↗

A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancersSemantic proximity Read ↗

FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent mannerSemantic proximity Read ↗

FSP1 and NRF2 independently contribute to ferroptosis resistance in KEAP1 mutant non-small cell lung carcinomaSemantic proximity Read ↗

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read ↗

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.Semantic proximity Read ↗

Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy.Semantic proximity Read ↗

The tumor suppressive role of KEAP1: Underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.Semantic proximity Read ↗

Ferroptosis Resistance: Redundant Antioxidant Networks Is a Barrier to Cancer TherapySemantic proximity Read ↗

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Ferroptosis and Nrf2 Signaling in Head and Neck Cancer: Resistance Mechanisms and Therapeutic ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.